ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,254 GBX | +0.04% |
|
+3.44% | +6.15% |
| 10:50am | ASTRAZENECA : JP Morgan reaffirms its Buy rating | ZD |
| 10:12am | AstraZeneca: Voydeya approved in the EU as a treatment for HPN | CF |
Presentation Operator MessageOperator (Operator)Good morning to those from the U.K. and U.S., ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
138.8
USD
Average target price
161.7
USD
Spread / Average Target
+16.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.15% | 215B | |
| +25.46% | 659B | |
| +26.66% | 557B | |
| -4.86% | 359B | |
| +16.44% | 322B | |
| +8.34% | 297B | |
| +7.18% | 210B | |
| -6.05% | 200B | |
| -8.79% | 149B | |
| -5.59% | 146B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Transcript : AstraZeneca PLC, H1 2022 Earnings Call, Jul 29, 2022
